Detalhe da pesquisa
1.
Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety.
Hematol Oncol
; 42(1): e3222, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37740931
2.
Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysis.
Br J Clin Pharmacol
; 90(3): 748-758, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855131
3.
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Eur J Haematol
; 104(5): 435-442, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31883396